Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction.
Saved in:
| Title: | Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction. |
|---|---|
| Authors: | England E; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Rees DG; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Scott IC; Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Carmen S; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Chan DTY; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Chaillan Huntington CE; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Houslay KF; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Erngren T; Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Penney M; Early Oncology DMPK, Oncology R&D, AstraZeneca, Cambridge, UK., Majithiya JB; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Rapley L; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Sims DA; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Hollins C; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Hinchy EC; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Strain MD; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Kemp BP; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Corkill DJ; Bioscience In Vivo, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., May RD; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Vousden KA; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Butler RJ; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Mustelin T; Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, USA., Vaughan TJ; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Lowe DC; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Colley C; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Cohen ES; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. suzanne.cohen@astrazeneca.com. |
| Source: | Scientific reports [Sci Rep] 2023 Jun 17; Vol. 13 (1), pp. 9825. Date of Electronic Publication: 2023 Jun 17. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2045-2322 |
|---|---|
| DOI: | 10.1038/s41598-023-36642-y |
